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Abstract
Background: New tools are required to improve tuberculosis (TB) diagnosis and treatment,
including enhanced ability to compare new treatment strategies. The ELISPOT assay uses
Mycobacterium tuberculosis-specific antigens to produce a precise quantitative readout of the
immune response to pathogen. We hypothesized that TB patients in The Gambia would have
reduced ELISPOT counts after successful treatment.
Methods: We recruited Gambian adults with sputum smear and culture positive tuberculosis for
ELISPOT assay and HIV test, and followed them up one year later to repeat testing and document
treatment outcome. We used ESAT-6, CFP-10 and Purified Protein Derivative (PPD) as stimulatory
antigens. We confirmed the reliability of our assay in 23 volunteers through 2 tests one week apart,
comparing within and between subject variation.
Results: We performed an ELISPOT test at diagnosis and 12 months later in 89 patients. At
recruitment, 70/85 HIV-negative patients (82%) were ESAT-6 or CFP-10 (EC) ELISPOT positive,
77 (90%) were PPD ELISPOT positive. Eighty-two cases (96%) successfully completed treatment:
44 (55%; p < 0.001) were EC ELISPOT negative at 12 months, 17 (21%; p = 0.051) were PPD
ELISPOT negative. Sixty (73%) cured cases had a CFP-10 ELISPOT count decrease, 64 (78%) had
an ESAT-6 ELISPOT count decrease, 58 (70%) had a PPD ELISPOT count decrease. There was a
mean decline of 25, 44 and 47 SFU/2 × 105 cells for CFP-10, ESAT-6 and PPD respectively (p <
0.001 for all). Three of 4 HIV positive patients were cured, all 3 underwent ELISPOT reversion; all
4 not cured subjects (3 HIV-negative, 1 HIV positive) were ESAT-6, CFP-10 and PPD ELISPOT
positive at 12 months.
Conclusion: Successful tuberculosis treatment is accompanied by a significant reduction in the M.
tuberculosis-specific antigen ELISPOT count. The ELISPOT has potential as a proxy measure of TB
treatment outcome. Further investigation into the decay kinetics of T-cells with treatment is
warranted.
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Background
Tuberculosis (TB) causes an estimated 2 million deaths
per year [1], the overwhelming majority occur in develop-
ing countries [2], and Mycobacterium tuberculosis infects
approximately one third of the world's population [3].
While the incidence of TB has stabilised or is on the
decrease in many parts of the world, the incidence rate is
rising by approximately 6% per year in Africa [4]. New
diagnostic tools for TB, new and enhanced treatment strat-
egies, plus efficacy markers to compare them, are needed
to help combat the epidemic. These need to be shown to
be useful in TB-endemic tropical settings.
T-cell based immuno-assays have promise for the diagno-
sis of TB disease and M. tuberculosis infection. The ex-vivo
ELISPOT can precisely enumerate interferon-gamma
(IFN-γ) producing T-cells sensitised to M. tuberculosis anti-
gens and we have shown that the quantitative ELISPOT
count reflects the infectious load of M. tuberculosis in The
Gambia [5]. Noting this property, we hypothesized that
the ELISPOT count would decrease as a response to a
course of anti-TB therapy in TB cases. Therefore, as a first
step towards identifying whether the ELISPOT might be
an efficacy marker in this way in The Gambia, we assessed
the ELISPOT response in TB cases before and after treat-
ment.
Methods
Participants
Nested in a large case contact study in The Gambia [6], we
recruited sputum smear and culture positive adult TB
cases for the study. We took a 10 ml blood sample from
each case at the time of diagnosis and followed them up
12 months later to take a repeat sample. The National TB
Control Program gave each case a standard six-month
course of free treatment by Directly Observed Therapy,
short course (DOTS) to all patients. Ethical approval for
this study was obtained from the joint MRC – Gambian
Government Ethics board. Informed consent was
obtained from all study participants.
We tracked the patients' clinical outcome through follow-
up interviews and corroborated the results with clinical
records (TB treatment cards and clinic treatment register).
Patients who were found at follow-up to have successfully
completed their treatment, and who were well at time of
12-month blood test (no cough/sweats/weight loss, or
other TB symptoms since the completion of treatment),
were categorised as "cured." Others were further catego-
rised according to standard WHO definitions [7]: they
were defined as "defaulted" if treatment was interrupted
for two consecutive months or they were defined as
"failed treatment" if they remained sputum smear positive
at 4 months or later during a course of treatment.
Laboratory procedures
Sputum smears were prepared and stained with auramine-
phenol [8] and the results were confirmed by Ziehl-
Neelsen staining. Decontaminated specimens were inocu-
lated into Lowenstein-Jensen medium and BACTEC 9000
liquid medium for the isolation and identification of M.
tuberculosis, as described previously [9]. HIV testing was
done by enzyme linked immunosorbent assay (ELISA;
Wellcome Laboratories, Dartford, Kent, UK) and by type-
specific Western blot (New LAV Blot I and New LAV Blot
II, Diagnostics Pasteur, Marnes-la-Coquette, France). All
data were entered using double data entry into an ACCESS
database and verified.
The ex-vivo ELISPOTs were performed in duplicate as pre-
viously described [10]. Overlapping peptides spanning
the length of ESAT-6 and CFP-10 (ABC, Imperial College,
London, UK) were each divided into peptide pools, and
used at 5 μg/ml. Purified Protein Derivative (PPD; Mtb,
RT49, Statins Serum Institut, Copenhagen, Denmark) was
used at 10 μg/ml. The positive control was Phytohae-
maglutinin (PHA; Sigma-Aldrich, UK). Assays were scored
by an automated ELISPOT reader (AID-GmbH, Strass-
berg, Germany). A positive test well was pre-defined as
containing at least 10 Spot Forming Units (SFUs) more
than, and at least twice as many as, negative control wells.
PHA wells were set to at least 150 SFUs above negative
control wells, which were required to have less than 30
SFUs to be included in the analysis. Antigen SFUs were
reported as number of SFUs above the negative control
SFUs.
Reliability of the ELISPOT assay
We assessed the reliability of the ELISPOT assay in two
ways. Firstly, to assess the within-subject variability, we
tested each antigen in duplicate for each subject and com-
pared the within and the between subject variability by fit-
ting a random effects model for subject. Within our large
case contact study, we used ELISPOT results from consec-
utively recruited TB case contacts: 1223 duplicate results
for ESAT-6 peptides and 1182 duplicate results for CFP-10
peptides. For CFP-10 the between subject standard devia-
tion was 29.4 spots and the within subject standard devi-
ation was 3.6 spots. For ESAT-6, the between-subject
standard deviation was 38.9 spots and the within-subject
standard deviation was 4.2 spots. Therefore the within-
subject variability was very small compared to the
between-subject variability. Secondly, to assess the day-to-
day variability, we recruited 23 adult volunteers from the
general community and conducted an ELISPOT test fol-
lowed by a repeat test after 1 week. Twelve volunteers had
a negative test initially: none of these had a positive test
after 1 week. Eleven volunteers had a positive test initially:
only one of these had a negative test after one week. For
those who were positive at both time points the differ-BMC Infectious Diseases 2006, 6:66 http://www.biomedcentral.com/1471-2334/6/66
Page 3 of 6
(page number not for citation purposes)
ences between the SFUs at the two time points were: -15,
-7, -4, -1, 3, 5, 6, 6, 12, and 35 SFU respectively.
Data management and analysis
All data were entered via double data entry into an Access
database and checked for errors. Statistical analysis was
conducted using SPSS software. Qualitative outcomes
were compared by a test of proportions and quantitative
outcomes by student's t-test (paired). When necessary (for
ESAT-6 and CFP-10) log (base 10) transformations were
performed.
Results
We identified 151 sputum smear and culture positive sub-
jects who had a satisfactory ELISPOT test result from
blood tests taken at the time of diagnosis. At 12 months,
97 (64%) of these cases were found, agreed to be bled and
had a blood sample taken. From these, a satisfactory ELIS-
POT result was obtained in 89 subjects (92% technical
success); 7 had a failed ELISPOT test because of a weak
positive control count and one had too high a negative
control count. Table 1 shows the basic characteristics of
the 89 cases included in the study. Sixty-two (70%) were
men and the mean age was 32 yrs (range 18 – 80 yrs). Four
cases (4%) were HIV positive.
Figure 1 shows the qualitative ELISPOT results at recruit-
ment and 12 months in the 85 HIV negative cases. At
recruitment, 70 cases (82%) were ESAT-6 or CFP-10 (EC)
ELISPOT positive, and 77 (90%) were PPD ELISPOT pos-
itive. Eighty-two subjects (96%) successfully completed
the 6-month TB drug-treatment regimen and were consid-
ered to be cured. Of these, 44 (54%) were EC ELISPOT
negative at 12 months, and 17 (21%) were PPD ELISPOT
negative. For ESAT-6 and CFP-10, the differences between
recruitment and 12 months were highly significant (p <
0.001, test of proportions). The difference in PPD ELIS-
POT positivity was of borderline significance (p = 0.051).
Three cured cases were EC ELISPOT negative at recruit-
ment but positive at 12 months whereas 7 cured cases
were PPD ELISPOT negative at recruitment but positive at
12 months. There were no significant differences in age,
sex or ethnicity between the 34 cured cases who had a pos-
itive EC ELISPOT test at both recruitment and at 12
months and those who either reverted from positive to a
negative ELISPOT, or were negative at both time points
(data not shown).
Figure 2 shows the quantitative change in the ELISPOT
counts between recruitment and 12 months for the 82
cured cases. Sixty (73%) cases had a decrease in their CFP-
10 ELISPOT count at 12 months and 64 (78%) had a
decrease in their ESAT-6 ELISPOT count. Fifty-eight (70%)
cured cases had decrease in their PPD ELISPOT counts.
For the three tests, there was a mean decline in counts at
12 months of 25, 44 and 47 SFU/2 × 105 cells for CFP-10,
ESAT-6 and PPD respectively, all highly significant
(p < 0.001). Six (7%) cured cases had an increase in either
Table 1: Demographics of 89 smear and culture positive tuberculosis patients
Characteristic (n = 89)
All patients
Age, years
Mean 32
Median (range) 26 (18 – 80)
Male Sex 62 (70%)
Ethnic group
Mandinka 40 (45%)
Jola 15 (17%)
Wolof 13 (15%)
Fula 11 (12%)
Other 10 (11%)
HIV-negative 85/89
Outcome of TB treatment
Completed treatment and cured 82/85 (96%)
Defaulted from treatment 2/85 (3%)
Treatment failed (remained sputum +ve) 1/85 (1%)
HIV-positive 4/89
Outcome of TB treatment
Completed treatment and cured 3/4 (75%)
Defaulted from treatment 1/4 (25%)BMC Infectious Diseases 2006, 6:66 http://www.biomedcentral.com/1471-2334/6/66
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their ESAT-6 or CFP-10 ELISPOT count of at least 10 SFU
(Figure 2a and 2b), including one who had an increased
count for both antigens; 18 (21%) cases, had an increased
PPD ELISPOT count of at least 10 SFU (Figure 2c) which
included 4 of the 6 with increased EC counts.
Three HIV-negative cases were defined as "not cured".
Two were defined as "defaulted from drug therapy"; both
subsequent died with symptoms suggestive of TB recur-
rence after the 12-month blood test. One case was defined
as "treatment failure": he was sputum-smear positive at
the end of his six months of TB treatment despite good
compliance. All three of these subjects were ESAT-6, CFP-
10 and PPD ELISPOT positive at 12 months.
Three of four HIV positive cases completed the TB treat-
ment course and were healthy at the time of the 12-month
testing. The EC ELISPOT tests in all 3 reverted from posi-
tive to negative. One HIV-positive subject defaulted from
TB therapy: all three of his ELISPOT tests (CFP-10, ESAT-
6 and PPD) were positive at 12 months.
Discussion
As far as we are aware this is the largest study so far to eval-
uate ELISPOT reversion after anti-TB treatment. A signifi-
cant proportion of patients who successfully completed a
course of standard TB treatment changed from a positive
to a negative EC ELISPOT 12 months after their initial
diagnosis. There was also a significant reduction in mean
ESAT-6, CFP-10 and PPD ELISPOT counts. Seven per cent
of cases had an increase in their ELISPOT counts for either
ESAT-6 or CFP-10, compared to 21% for PPD.
Paired recruitment and 12 months quantitative counts of  Spot Forming Units (SFU)/2 × 105 cells in ELISPOT tests  using CFP-10 (Fig. 2), E-SAT6 (Fig. 3) and PPD (Fig. 4) as  stimulatory antigens for cured, HIV-negative patients (n = 82) Figure 2
Paired recruitment and 12 months quantitative counts of 
Spot Forming Units (SFU)/2 × 105 cells in ELISPOT tests 
using CFP-10 (Fig. 2a), E-SAT6 (Fig. 2b) and PPD (Fig. 2c) as 
stimulatory antigens for cured, HIV-negative patients (n = 
82). Filled black squares (■) represent the SFU count at 
recruitment; white squares () represent SFU counts 12 
months later, after successful completion of TB treatment. 
The change in counts between the two timepoints is repre-
sented by the linking vertical bar. With all three stimulatory 
antigens, the average within-subject decline in SFU counts is 
highly significantly (p < 0.001).
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The data reported here cannot be explained by the inher-
ent variability of the ELISPOT readout and are consistent
with those from other, albeit small, studies from other set-
tings. Two previous studies of tuberculosis patients in the
United Kingdom (UK; n = 4) and Italy (n = 18) reported a
decline in quantitative ESAT-6 ELISPOT counts after drug
treatment [11,12], However, in one UK study, ESAT-6
ELISPOT counts in 10 patients who had completed TB
therapy were marginally but not significantly higher than
the counts in 8 different patients early in their TB treat-
ment course [13].
The  ex vivo ELISPOT response is thought to identify
recently activated lymphocytes with immediate effector
memory that persist only a limited time in circulation
once antigen is cleared [14]. It follows therefore that anti-
gen withdrawal after anti-TB therapy would be accompa-
nied by a decline in T cell frequencies. There are several
possible explanations why even 'specific' antigen (ESAT-6
and CFP-10) counts did not universally drop below the
pre-defined, and relatively conservative, cut-off for posi-
tivity (10 SFU) in The Gambia. Firstly, some patients may
have been re-exposed to M. tuberculosis after the comple-
tion of treatment and re-aquired latent M. tuberculosis
infection. Secondly, they may have been exposed to envi-
ronmental mycobacteria, commonly encountered in the
tropics, which share the esat-6 and cfp-10 genes (eg. M.
marinum). Thirdly, and most intriguingly, there is evi-
dence that in some individuals there is persistence of a
population of activated T cells in the absence of direct
mycobacterial antigen stimulation, even for several years
after completing therapy [15].
Having determined that, even in this TB-endemic tropical
setting, ELISPOT counts decrease significantly in TB cases
after treatment, we will explore the decay kinetics of spe-
cific antigen T-cell responses during the course of treat-
ment. It has been suggested that the decay rate of antigen-
specific T-cells is approximately 5.5% of the total count
per week, [11] which would lead to an approximately
90% decline in counts over 40 weeks. In a small study in
South Africa, Nicol et al showed that 10 children with TB
had an initial rise, then a decline in ELISPOT counts over
a 6-month treatment course [16]. Vekemans et al, in The
Gambia, showed that TB patients had relatively low T cell
responses to purified mycobacterial antigens, compared
to healthy controls with evidence of M. tuberculosis infec-
tion [17]. An obvious explanation for these findings is
that patients at diagnosis have suppressed T cell responses
because they are unwell. M. tuberculosis can itself interfere
with IFN-γ signalling [18], providing another possible
explanation. Other factors may also be important, such as
increased early antigen presentation as a result of patho-
gen killing at the onset of antibiotic therapy. Thus the
implied trajectory of cellular kinetics is of T-cell responses
that increase early in treatment, then decline as the M.
tuberculosis antigen load diminishes. A possible sampling
frame would be to conduct repeat ELISPOT tests at 1
month, 2 months (to compare with sputum conversion in
smear positive cases), 4 months and 6 months. We also
aim to follow those who are persistently ELISPOT positive
as a cohort over time.
While it is of interest that all four of the treatment failures
(3 HIV-negative, 1 HIV-positive) in our study had positive
EC and PPD ELISPOT tests at 12 months, larger numbers
of similar cases will be required to identify the true sensi-
tivity of ELISPOT persistence with respect to treatment
failure. That a few cured cases had a rise in ELISPOT
counts for ESAT-6 and/or CFP-10 suggests that the posi-
tive predictive value of this finding for treatment failure is
not 100% in The Gambia. However, it is quite possible
that 'cured patients' may relapse at a later date.
Conclusion
There is now compelling evidence from a variety of set-
tings that a significant decrease in the ELISPOT count
occurs in TB patients that are cured by TB treatment. This
may have important implications for clinical practice:
effective monitoring of response to treatment, tailoring
the duration of anti-tubercular drug therapy, comparing
the efficacy of new therapies (including therapeutic vac-
cines), and rationalising the basis for treatment of latent
infection are all possible applications. Further studies are
required to define the sensitivity and predictive value of
ELISPOT reversion and persistence in relation to TB treat-
ment, to find the best time to conduct a repeat test, and to
identify clinical and immunological risk factors for per-
sistence of an ELISPOT response and whether such indi-
viduals are at any risk of disease recurrence. A repeat
ELISPOT test at 12 months reflects the efficacy of a course
of anti-TB treatment even in a TB endemic tropical setting.
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